<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770000</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530+Romidepsin-1805</org_study_id>
    <nct_id>NCT03770000</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma</brief_title>
  <official_title>An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of
      Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in Patients with T cell lymphoma</measure>
    <time_frame>28 days</time_frame>
    <description>The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 28-day cycle of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) with Tenalisib and Romidepsin combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>No. of patients with partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) with Tenalisib and Romidepsin combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time period from the response achieved in patient until the disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
    <description>Assessment of Cmax in subjects treated with Tenalisib and Romidepsin combination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib, BID orally daily</description>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Romidepsin IV</description>
    <arm_group_label>Tenalisib+Romidepsin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed T-cell lymphomas at the enrolling institution.

          2. Disease status as defined as relapsed or progressed patients who have received at
             least one systemic therapy.

          3. The patients should have received NOT more than three prior systemic combination
             chemotherapies

          4. PTCL patients must have measurable disease defined as at least one bidimensional
             measurable lesion with minimum measurement of &gt; 1.5 cm in the longest diameter.

          5. Must have ECOG performance status ≤ 2

          6. Adequate bone marrow, liver and renal function in line with below mentioned laboratory
             requirements.

               1. Hemoglobin ≥8.0 g/dL

               2. Absolute neutrophil count (ANC) ≥1,000/µL

               3. Platelet count ≥75,000/μL

               4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)

               5. AST (SGOT) and ALT (SGPT) ≤ 3 x ULN; ≤ 5 ULN in case of liver involvement

               6. Calculated creatinine clearance (CrCl) &gt; 50 ml/min by Cockcroft-Gault formula

          7. Use of an effective means of contraception for women of childbearing potential and men
             with partners of childbearing potential.

          8. Provide written informed consent prior to any study-specific screening procedures.

          9. Willingness and capability to comply with the requirements of the study

        Exclusion Criteria:

          1. Patient receiving anticancer therapy including any investigational therapy ≤3 weeks or
             5 half-lives (whichever is shorter) prior to C1D1.

          2. Patient who discontinued prior therapy with PI3K inhibitors or HDAC inhibitors due to
             drug toxicity.

          3. PTCL patients with Allo-SCT on active GVHD or immunosuppression therapy within 3
             months prior to C1D1. CTCL patients with the history of Allo-SCT will be excluded.

          4. Patient with medical conditions requiring the use of systemic immunosuppressive
             medications (&gt; 20 mg/day of prednisone or equivalent).

          5. Severe bacterial, viral or mycotic infection requiring systemic treatment.

          6. Known seropositive requiring anti-viral therapy for human immunodeficiency virus (HIV)
             infection.

          7. Known seropositive requiring anti-viral therapy for hepatitis B virus (HBV) infection
             OR evidence of active hepatitis B infection as defined by detectable viral load if the
             antibody tests are positive..

          8. Known seropositive requiring anti-viral therapy for hepatitis c virus (HCV) infection
             OR patients with positive hepatitis C virus Ab.

          9. Subjects with active EBV unrelated to underlying lymphoma (positive serology for anti-
             EBV VCA IgM antibody and negative for anti-EBV EBNA IgG antibody, or clinical
             manifestations and positive EBV PCR consistent with active EBV infection.

         10. Subject with active CMV (positive serology for anti-CMV IgM antibody and negative for
             anti-CMV IgG antibody and positive CMV PCR with clinical manifestations consistent
             with active CMV infection) and requiring therapy.

         11. Uncontrolled or significant cardiovascular disease including, but not limited to:

               -  Congenital long QT syndrome.

               -  QTcF interval &gt; 450 msec

               -  Myocardial infarction or stroke/TIA within the past 6 months

               -  Uncontrolled angina within the past 3 months

               -  Significant ECG abnormalities including 2nd degree atrio- ventricular (AV) block
                  (AV) block type II, 3rd degree AV block.

               -  History of clinically significant arrhythmias (such as ventricular tachycardia,
                  ventricular fibrillation or torsades de pointes),

               -  History of other clinically significant heart disease (ie, cardiomyopathy,
                  congestive heart failure with NYHA functional classification III-IV,
                  pericarditis, significant pericardial effusion)

               -  Requirement for daily supplemental oxygen therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Swaminathan P Iyer, MD</last_name>
    <phone>+001 713 745 1113</phone>
    <email>clinicaltrials@rhizen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prajak Barde, MD</last_name>
    <phone>+41 32 580 0175</phone>
    <email>clinicaltrials@rhizen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Mohrbacher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Hellen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai Z Weiyun, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jessica Avila</last_name>
      <email>Jessica.Avila@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley Haverkos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami-Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Pablo Alderuccio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jo Lechowicz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>David J Reagan</last_name>
      <email>david.j.reagan@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy M Kuzel, MD, FACP</last_name>
    </contact>
    <contact_backup>
      <last_name>Jessica L Chorak</last_name>
      <email>Jessica_L_Chorak@rush.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anusha Vallurupalli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, St Matthews Campus</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Ambrose Stevens, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Krentz, G Erin</last_name>
      <email>Erin.Krentz@nortonhealthcare.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumana Devata, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Feldman Tatyana Feldman, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Azzollini, Kelly</last_name>
      <email>Kelly.Azzollini@hackensackmeridian.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchitra Sundaram, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Jagadeesh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Okada, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-5505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishitha Reddy, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dudley, V Channing</last_name>
      <email>channing.v.dudley@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center,</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swaminathan P Iyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center,</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auris Huen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell Lymphoma</keyword>
  <keyword>RP6530</keyword>
  <keyword>Tenalisib</keyword>
  <keyword>Romidepsin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

